Stocktoria
Immuneering Corp IMRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-30
Immuneering Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316,952 | $2.1M |
| Gross profit | — | — | $0 | $158,830 | $926,888 |
| R&D expense | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M |
| Income tax | $0 | — | — | — | -$307,485 |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M |
| EPS (diluted) | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 |
| Operating cash flow | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M |
| Free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M | -$30.9M |
| Cash & equivalents | $128.6M | $36.1M | $59.4M | $72.6M | $74.9M |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M |
| Shareholders' equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M |
Source: SEC EDGAR filings · CIK 0001790340 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.